AstraZeneca in Merger Talks with Bristol-Myers Squibb, Financial Times Reports
AstraZeneca is in merger talks with Bristol-Myers Squibb, the Financial Times reported, citing people familiar with the matter, with Reuters picking up the story on August 2. A combined company would have a market value of close to $400 billion, and the two sides have held multiple rounds of discussions over recent months. The deal could be finalised soon but also faces delay or collapse; AstraZeneca declined to comment and Bristol-Myers Squibb has not responded.
Why it matters: A potential merger would create one of the world's largest pharmaceutical companies by market value.